Want to join the conversation?
Pharmaceutical company $MYL said that it has agreed to acquire Meda, an international specialty pharmaceutical company via a recommended public offer and a transaction valued at $9.9Bil, including synergies and approx. $1.1Bil in EBITDA. This combination provides 2015 combined revenues of $11.8Bil.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)